‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
The Beacon
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
30
00:00:00
/ 00:02:18
30